Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori

Saudi Journal of Gastroenterology

Volumn 16, Issue 1, 2010, Pages 14-18

  Hasan, Salman R ^a   Vahid, Vahabzadeh ^b   Reza, Pahlvanzadah M ^b   Roham, Salman R ^c  

^a Depatments of Internal Medicine

^b YAZD UNIVERSITY   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Eradication; Furazolidone; Helicobacter pylori

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; OMEPRAZOLE; UREASE;

ADULT; ANOREXIA; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM ULCER; FATIGUE; FECES; FEMALE; FEVER; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TASTE DISORDER; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; URTICARIA; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 75649113856     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.58762     Document Type: Article

References (44)

1. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995;9:59-69.
2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994 6;272:65-69
3. Abu-Mahfouz MZ, Prasad VM, Santogade P, Cutler AF. Helicobacter pylori recurrence after successful eradication: 5-year follow-up in the United States. Am J Gastroenterol 1997;92:2025-2028
4. Tytgat GN. Review article: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994;8:359-368
5. De Boer WA, Tytgat GN. Regular review: Treatment of Helicobacter pylori infection. BMJ 2000;320:31-34
6. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001;15:411-416
7. Graham DY, Qureshi WA. Antibiotic-resistant H pylori infection and its treatment. Curr Pharm Des 2000;6:1537-1544
8. Tanabe H, Watari J, Shibata N, Satoh T, Yokota K, Kohgo Y. Usefulness of new triple therapy containing PPI. Nippon Rinsho 2001;59:314-318
9. van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: A review of the world literature. Helicobacter 1996;1:6-19.
10. Malekzadeh R, Merat S, Derakhshan MH, Siavoshi F, Yazdanbod A, Mikaeli J, et al. Low Helicobacter pylori radication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003;18:13-17
11. Kaviani MJ, Malekzadeh R, Vahedi H, Sotoudeh M, Kamalian N, Amini M, et al. Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial. Eur J Gastroenterol Hepatol 2001;13:915-919
12. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000;14:211-215
13. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994;89:S116-28.
14. Roghani HS, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol 2003;18:778-782
15. Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000;14:299-303.
16. Saberi-Firoozi M, Massarrat S, Zare S, Fattahi M, Javan A, Etaati H, et al. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: A prospective, randomized, controlled study. Am J Gastroenterol 1995;90:1419-1423
17. Roghani HS, Massarrat S, Pahlewanzadeh MR, Dashti M. Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains. Eur J Gastroenterol Hepatol 1999;11:709-712
18. Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001;47:459-461 (Pubitemid 32303414)
19. Drouin E. Helicobacter pylori: Novel therapies. Can J Gastroenterol 1999;13:581-583 Review.
20. Thijs JC, Van Zwet AA, Moolenaar W, Oom JA, De Korte H, Runhaar EA. Short report: Clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. Aliment Pharmacol Ther 1994;8:131-134
21. Dani R, Queiroz DM, Dias MG, Franco JM, Magalhães LC, Mendes GS, et al. Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. Aliment Pharmacol Ther 1999;13:1647-1652
22. Fennerty MB, Lieberman DA, Vakil N, Magaret N, Faigel DO, Helfand M. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med 1999;159:1562-1566
23. Mégraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997;11:43-53.
24. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999;12:341-347
25. Reddy R, Osato M, Gutierrez O. Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the US (Abstract). Gastroenterology 1996;110:A236.
26. O'Morain C, Montague S. Challenges to therapy in the future. Helicobacter 2000;5:S23-6; discussion S27-31
27. New antidepressant drug opens up important treatment and safety options. Ir Med J 1996;89:214.
28. McNamara D, O'Morain C. Consensus guidelines: Agreement and debate surrounding the optimal management of Helicobacter pylori infection. Can J Gastroenterol 2000;14:511-517
29. Tytgat GNJ. Aspects of Anti-Helicobacter pylori, Basic Mechanism to Clinical Cure 1996. Dordrecht: Kluwer Academic 1996; 304-347
30. al-Assi MT, Ramirez FC, Lew GM, Genta RM, Graham DY. Clarithromycin, tetracycline, and bismuth: A new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994;89:1203-1205
31. Jawetz E. Drugs with specialized indication and urinary antiseptic. In: K-atzung BG (ed). Basic and Clinical Phar-macology, 6th ed. California: Appleton and Lange: 1995. p. 738.
32. Smith JN. Drugs used to treat amebiasis and other intestinal protozoal infections. In: dark WG, Brater DC, Johnson AR, eds. Goth's Medical Pharmacology, 13th ed. New York, Mosby: St Louis; 1992. p. 689.
33. Howden A, Boswell P, Tovey F. In-vitro sensitivity of Campylobacter pyloridis to furazolidone. Lancet 1986;2:1035.
34. Van Zwet AA, Thijs JC, van der Wouden EJ, Kooy A. Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Aliment Pharmacol Ther 1997;11:533-535
35. Xiao SD, Liu WZ, Xia DH, Jiang SJ, Wang RN, Zhang ZH, et al. The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori--a randomized double-blind placebo-controlled clinical trial. Hepatogastroenterology 1990;37:503-506
36. Liu WZ, Xiao SD, Hu PJ, Lu H, Cui Y, Tytgat GN. A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine. Aliment Pharmacol Ther 2000;14:1519-1522
37. Liu WZ, Xiao SD, Shi Y, Wu SM, Zhang DZ, Xu WW, et al. Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:317-322
38. Xiao SD, Liu WZ, Hu PJ, Ouyang Q, Wang JL, Zhou LY, et al. A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. Aliment Pharmacol Ther 2001;15:81-86
39. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FA, Osato MS, et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: Prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001;45:306-308
40. Mendonça S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 2000;5:79-83.
41. Malekzadeh R, Pourkhajeh A, Siavoshi F. Antibiotic resistance of Helicobacter pylori to antibiotics in Iran. Gastroenterology 1999;116:244.
42. Gilman AG, Rail TW, Niles AS, Taylor P, eds. Goodman and Gillman's Pharmacological basis of therapeutics. 8th ed. NewYork: Pergamon Press; 1991
43. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004;19:89-93.
44. de Boer WA. Bismuth triple therapy: Still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999;11:697-700.